PRLD Prelude Therapeutics

Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences

Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences

WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences:

  • Morgan Stanley 19th Annual Global Healthcare Conference

    Fireside chat at 11:45 a.m. ET on Thursday, September 9, 2021
  • H.C. Wainwright 23rd Annual Global Investment Conference

    Corporate presentation at 7:00 a.m. ET on Monday, September 13, 2021

A live webcast of the Morgan Stanley fireside chat and H.C. Wainwright presentation can be accessed under “Events & Presentations” in the Investor Section of the Company’s website, , where a replay of the events will also be available for a limited time.

About Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude’s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company’s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.

Investor Contact:

Stacey Jurchison

Executive Director, Corporate Affairs

Melissa Forst

Argot Partners

212.600.1902

Media Contact:

Deborah Elson

Argot Partners

212.600.1902



EN
02/09/2021

Underlying

PRLDPrelude Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Prelude Therapeutics

 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Receives FDA Clearance of Investigational New Dru...

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT12396, a mutant-selective J...

February 3, 2026 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from...

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026 First disclosure of a mutant calreticulin (mCALR) targeted degrader antibody conjugate (DAC) with a novel CDK9 degrader payload JAK2V617F and mCALR are the two primary driver mutations responsible for disease progression and poor prog...

December 6, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and ...

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and CALR-targeted degrader antibody conjugate (DAC) program were both accepted for oral presentations at the American Society of Hematology (ASH) 67th Annual Meeting in December Current cash runway into 20...

November 12, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Announces Strategic Business Update

Prelude Therapeutics Announces Strategic Business Update Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company’s preliminary estimates, and potentially into the third quarter of 2028 if Incyt...

November 4, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte ...

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milesto...

November 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch